Sanofi SA banner

Sanofi SA
PAR:SAN

Watchlist Manager
Sanofi SA Logo
Sanofi SA
PAR:SAN
Watchlist
Price: 80.98 EUR -0.05% Market Closed
Market Cap: €98.2B

EV/EBITDA

10.5
Current
8%
More Expensive
vs 3-y average of 9.6

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
10.5
=
Enterprise Value
€106.6B
/
EBITDA
€10.1B

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
10.5
=
Enterprise Value
€106.6B
/
EBITDA
€10.1B

Valuation Scenarios

Sanofi SA is trading above its 3-year average

If EV/EBITDA returns to its 3-Year Average (9.6), the stock would be worth €74.66 (8% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-38%
Maximum Upside
No Upside Scenarios
Average Downside
21%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 10.5 €80.98
0%
3-Year Average 9.6 €74.66
-8%
5-Year Average 9.7 €75.21
-7%
Industry Average 6.5 €50.37
-38%
Country Average 7.3 €56.32
-30%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
€106.6B
/
Jan 2026
€10.1B
=
10.5
Current
€106.6B
/
Dec 2026
€15.1B
=
7.1
Forward
€106.6B
/
Dec 2027
€15.8B
=
6.7
Forward
€106.6B
/
Dec 2028
€17.7B
=
6
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
FR
Sanofi SA
PAR:SAN
97.9B EUR 10.5 12.5
US
Eli Lilly and Co
NYSE:LLY
853.2B USD 28.4 42.1
US
Johnson & Johnson
NYSE:JNJ
544.6B USD 16.5 25.7
CH
Roche Holding AG
SIX:ROG
248.4B CHF 11.6 19.6
UK
AstraZeneca PLC
LSE:AZN
225.4B GBP 16.2 29.2
CH
Novartis AG
SIX:NOVN
222.8B CHF 12.4 20
US
Merck & Co Inc
NYSE:MRK
278.5B USD 9.5 15.3
IE
Endo International PLC
LSE:0Y5F
244.4B USD 386.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 8 10.8
US
Pfizer Inc
NYSE:PFE
155.3B USD 7.6 19.7
US
Bristol-Myers Squibb Co
NYSE:BMY
119.6B USD 7.1 16.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Sanofi SA
PAR:SAN
Average EV/EBITDA: 46.8
10.5
21%
0.5
US
Eli Lilly and Co
NYSE:LLY
28.4
21%
1.4
US
Johnson & Johnson
NYSE:JNJ
16.5
8%
2.1
CH
Roche Holding AG
SIX:ROG
11.6
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.2
12%
1.3
CH
Novartis AG
SIX:NOVN
12.4
5%
2.5
US
Merck & Co Inc
NYSE:MRK
9.5
4%
2.4
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8
2%
4
US
Pfizer Inc
NYSE:PFE
7.6
-8%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A
P/E Multiple
Earnings Growth PEG
FR
Sanofi SA
PAR:SAN
Average P/E: 21.2
12.5
16%
0.8
US
Eli Lilly and Co
NYSE:LLY
42.1
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
25.7
8%
3.2
CH
Roche Holding AG
SIX:ROG
19.6
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.2
25%
1.2
CH
Novartis AG
SIX:NOVN
20
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.3
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.7
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1.1

Market Distribution

In line with most companies in France
Percentile
65th
Based on 1 558 companies
65th percentile
10.5
Low
0.1 — 5.3
Typical Range
5.3 — 11.7
High
11.7 —
Distribution Statistics
France
Min 0.1
30th Percentile 5.3
Median 7.3
70th Percentile 11.7
Max 1 862.3

Sanofi SA
Glance View

Sanofi SA, a titan in the global healthcare sector, operates at the intricate crossroads of pharmaceutical innovation and patient care, driven by an unyielding commitment to improving human health. Emerging from its French roots, Sanofi has strategically positioned itself as a global leader in pharmaceuticals, vaccines, and consumer healthcare. The company’s success is essentially anchored in its capacity to consistently develop and commercialize life-saving drugs that address a myriad of health concerns, ranging from diabetes and cardiovascular diseases to rare disorders and oncology. Underlining its robust revenue engine is Sanofi's extensive R&D infrastructure that fuels its pipeline with groundbreaking therapies, reflecting a dynamic blend of scientific acumen and market-focused agility. By leveraging a hybrid model that integrates cutting-edge research with strategic alliances and acquisitions, Sanofi ensures a sustained presence in the highly competitive biopharmaceutical landscape. Enabling this network of innovation and impact is Sanofi's diverse portfolio, a balanced mix of specialty and established prescription drugs, over-the-counter products, and the critical arm of vaccines led by its Sanofi Pasteur division. This diversification offers both growth opportunities and stability, cushioning against the volatile tides of patent expirations and regulatory changes. Its vaccines segment, in particular, is a cornerstone in Sanofi's business, capturing substantial market share with products critical to global immunization efforts, further amplified by its role in responding to health emergencies like the COVID-19 pandemic. With a geographically expansive sales footprint and strategic marketing strategies, Sanofi capitalizes on emerging market opportunities while maintaining a strong presence in established regions, effectively making its bottom line a testimony to its operational excellence and strategic foresight in harmonizing science with humanity.

SAN Intrinsic Value
110.42 EUR
Undervaluation 27%
Intrinsic Value
Price €80.98
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett